Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Jean-Denis Karam, Nicolas Noel, Anne-Laure Voisin, Emilie Lanoy, Jean-Marie Michot, Olivier Lambotte
OBJECTIVE: Immune checkpoint inhibitor (ICI) antibodies constitute a new generation of cancer treatments, associated with immune-related adverse events (irAEs). A previous retrospective study of patients with metastatic melanoma (treated mostly with anti-CTLA4 antibodies) reported a serious infection rate of 7.3%. The main risk factors were corticoids and infliximab use. We sought to describe infections and risk factors among patients receiving anti-PD-1/PD-L1 ICIs. PATIENTS AND METHODS: We reviewed 200 medical records sampled randomly from a French prospective registry, which collates patients treated with anti-PD-1/PD-L1 ICIs...
December 2020: European Journal of Cancer
#2
Satoshi Tanaka, Ryo Asakawa, Kiyohide Komuta, Satoshi Tanizaki, Tomohiro Kanai, Muneyoshi Kuroyama, Kohki Shimazu, Junji Uchida, Takayuki Yakushijin, Kiyonobu Ueno
Immune checkpoint inhibitors (ICIs) improved the prognosis of patients with advanced lung cancers. The combination therapy of cytotoxic drugs and ICI is approved as first-line chemotherapy in non-small-cell lung cancer (NSCLC) and extensive disease small-cell lung cancer (ED-SCLC). It has been reported various immune-related adverse events (irAEs). We herein report a 65-year-old man with NSCLC who developed hepatitis and pancreatitis simultaneously during the combination immunochemotherapy. In the treatment of hepatitis and pancreatitis, the clinical course was different...
2020: Respiratory Medicine Case Reports
#3
JOURNAL ARTICLE
Takanobu Sasaki, Toshiharu Tabata, Ryo Nonomura, Yutaka Oshima, Hideki Mitomo, Naoya Ishibashi, Takafumi Sugawara, Noriaki Tezuka, Motoyasu Sagawa, Takashi Kondo, Naruo Yoshimura
OBJECTIVE: To retrospectively assess data on immune checkpoint inhibitors(ICIs)in an actual clinical setting, examine the factors that contribute to response and survival using real-world data, and compare the effectiveness of the 3 types of ICIs for patients with non-small cell lung cancer(NSCLC). METHODS: A retrospective analysis of 127 patients with NSCLC treated with ICIs at our hospital was conducted. RESULTS: Nivolumab(56 patients)showed a 3-year survival rate of 21...
October 2020: Gan to Kagaku Ryoho. Cancer & Chemotherapy
#4
MULTICENTER STUDY
Melissa Bersanelli, Sebastiano Buti, Diana Giannarelli, Alessandro Leonetti, Alessio Cortellini, Giuseppe Lo Russo, Diego Signorelli, Luca Toschi, Michele Milella, Sara Pilotto, Emilio Bria, Claudia Proto, Arianna Marinello, Giovanni Randon, Sabrina Rossi, Emanuele Vita, Giulia Sartori, Ettore D'Argento, Eva Qako, Elisa Giaiacopi, Laura Ghilardi, Anna Cecilia Bettini, Elena Rapacchi, Francesca Mazzoni, Daniele Lavacchi, Vieri Scotti, Lucia Pia Ciccone, Michele De Tursi, Pietro Di Marino, Daniele Santini, Marco Russano, Paola Bordi, Massimo Di Maio, Marco Audisio, Marco Filetti, Raffaele Giusti, Rossana Berardi, Ilaria Fiordoliva, Giulio Cerea, Elio Gregory Pizzutilo, Alessandra Bearz, Elisa De Carlo, Fabiana Cecere, Davide Renna, Roberta Camisa, Giuseppe Caruso, Corrado Ficorella, Giuseppe Luigi Banna, Diego Cortinovis, Matteo Brighenti, Marina Chiara Garassino, Marcello Tiseo
OBJECTIVES: In the most of cases, for non-small cell lung cancer (NSCLC) patients who progressed to previous immune checkpoint inhibitors (CKI) administered as first- or as second-line therapy, chemotherapy (CT) remains the only viable options in the absence of "druggable" mutations. We aimed to explore the efficacy of salvage chemotherapy after immunotherapy (SCAI) in advanced NSCLC patients. MATERIALS AND METHODS: We designed a retrospective, multicenter study, involving 20 Italian centers, with the primary objective of describing the clinical outcome of advanced NSCLC patients treated with SCAI at the participating institutions from November 2013 to July 2019...
December 2020: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
#5
REVIEW
Mei Feng, Zhongwei Zhao, Mengxuan Yang, Jiansong Ji, Di Zhu
Colorectal cancer (CRC) is the leading cause of cancer death worldwide. CRC therapeutic strategies include surgical resection, chemotherapy, radiotherapy, and other approaches. However, patients with metastatic CRC have worse prognoses. In recent years, T-cell-based immunotherapy has elicited promising responses in B-cell malignancies, melanoma, and lung cancer, but most CRC patients are resistant to immunotherapy, chemotherapy, and targeted therapy. Immune checkpoint inhibitors have shown encouraging results in non-small cell lung cancer, melanoma, and other cancers, but immune checkpoint blockade is only effective for CRC subset with microsatellite instability...
February 1, 2021: Cancer Letters
#6
JOURNAL ARTICLE
Lena Cvetkovic, Claudine Régis, Corentin Richard, Lisa Derosa, Antoine Leblond, Julie Malo, Meriem Messaoudene, Antoine Desilets, Wiam Belkaid, Arielle Elkrief, Bertrand Routy, Daniel Juneau
BACKGROUND: Immune checkpoint inhibitors (ICI) represent the backbone treatment for advanced non-small cell lung cancer (NSCLC). Emerging data suggest that increased gut microbiome diversity is associated with favorable response to ICI and that antibiotic-induced dysbiosis is associated with deleterious outcomes. 18 F-FDG physiologic colonic uptake on PET/CT increases following treatment with antibiotics (ATB) and could act as a surrogate marker for microbiome composition and predict prognosis...
May 2021: European Journal of Nuclear Medicine and Molecular Imaging
#7
JOURNAL ARTICLE
Meagan Montesion, Karthikeyan Murugesan, Dexter X Jin, Radwa Sharaf, Nora Sanchez, Ameet Guria, Max Minker, Gerald Li, Virginia Fisher, Ethan S Sokol, Dean C Pavlick, Jay A Moore, Alan Braly, Gaurav Singal, David Fabrizio, Leah A Comment, Naiyer A Rizvi, Brian M Alexander, Garrett M Frampton, Priti S Hegde, Lee A Albacker
Neoantigen presentation arises as a result of tumor-specific mutations and is a critical component of immune surveillance that can be abrogated by somatic loss of heterozygosity (LOH) of the human leukocyte antigen class I (HLA-I) locus. To understand the role of HLA-I LOH in oncogenesis and treatment, we utilized a pan-cancer genomic dataset of 83,644 patient samples, a small subset of which had treatment outcomes with immune checkpoint inhibitors (ICI). HLA-I LOH was common (17%) and unexpectedly had a non-linear relationship with tumor mutational burden (TMB)...
October 30, 2020: Cancer Discovery
#8
REVIEW
David Lang, Gerald Wahl, Nikolaus Poier, Sebastian Graf, David Kiesl, Bernd Lamprecht, Michael Gabriel
Cancer immunotherapy using immune-checkpoint inhibitors (ICI) has revolutionized the therapeutic landscape of various malignancies like non-small-cell lung cancer or melanoma. Pre-therapy response prediction and assessment during ICI treatment is challenging due to the lack of reliable biomarkers and the possibility of atypical radiological response patterns. Positron emission tomography/computed tomography (PET/CT) enables the visualization and quantification of metabolic lesion activity additional to conventional CT imaging...
October 28, 2020: Journal of Clinical Medicine
#9
JOURNAL ARTICLE
Yuri Ogura, Nobutaka Kataoka, Yusuke Kunimatsu, Yusuke Tachibana, Takumi Sugimoto, Nozomi Tani, Izumi Sato, Kazuki Hirose, Daishiro Kato, Takayuki Takeda
BACKGROUND: First-line chemoimmunotherapy (CIT) has improved overall survival (OS) and progression-free survival (PFS) outcomes among patients with non-small cell lung cancer (NSCLC). The immunological and nutritional statuses of patients fluctuate during treatment using immune checkpoint inhibitors, and are closely related to treatment outcomes. However, it is unclear whether these markers are significant in patients who are receiving CIT. METHODS: This retrospective single-center study evaluated 34 consecutive Japanese patients with NSCLC who were treated using first-line CIT...
October 30, 2020: Thoracic Cancer
#10
JOURNAL ARTICLE
Masaki Kanazu, Masahide Mori, Madoka Kimura, Kazumi Nishino, Takayuki Shiroyama, Izumi Nagatomo, Shoichi Ihara, Kiyoshi Komuta, Hidekazu Suzuki, Tomonori Hirashima, Toru Kumagai, Fumio Imamura
BACKGROUND: Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy is the standard treatment for advanced non-small cell lung cancer (NSCLC) harboring common EGFR mutations, such as exon 19 deletion or L858 point mutation. However, the effectiveness of EGFR-TKIs for patients with uncommon EGFR mutations remains unclear. METHODS: We retrospectively surveyed a consecutive database of NSCLC patients with EGFR mutations at five participating institutions...
October 29, 2020: Thoracic Cancer
#11
JOURNAL ARTICLE
Changxia Shao, Gerald Li, Lingkang Huang, Scott Pruitt, Emily Castellanos, Garrett Frampton, Kenneth R Carson, Tamara Snow, Gaurav Singal, David Fabrizio, Brian M Alexander, Fan Jin, Wei Zhou
Importance: Tumor mutational burden (TMB) is a potential biomarker associated with response to immune checkpoint inhibitor therapies. The prognostic value associated with TMB in the absence of immunotherapy is uncertain. Objective: To assess the prevalence of high TMB (TMB-H) and its association with overall survival (OS) among patients not treated with immunotherapy with the same 10 tumor types from the KEYNOTE-158 study. Design, Setting, and Participants: This retrospective cohort study evaluated the prognostic value of TMB-H, assessed by Foundation Medicine (FMI) and defined as at least 10 mutations/megabase (mut/Mb) in the absence of immunotherapy...
October 1, 2020: JAMA Network Open
#12
JOURNAL ARTICLE
Bairavi Shankar, Jiajia Zhang, Abdul Rafeh Naqash, Patrick M Forde, Josephine L Feliciano, Kristen A Marrone, David S Ettinger, Christine L Hann, Julie R Brahmer, Biagio Ricciuti, Dwight Owen, Yukihiro Toi, Paul Walker, Gregory A Otterson, Sandip H Patel, Shunichi Sugawara, Jarushka Naidoo
Importance: The spectrum of individual immune-related adverse events (irAEs) from anti-programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) has been reported widely, and their development is associated with improved patient survival across tumor types. The spectrum and impact on survival for patients with non-small cell lung cancer (NSCLC) who develop multisystem irAEs from ICIs, has not been described. Objective: To characterize multisystem irAEs, their association with survival, and risk factors for multisystem irAE development...
December 1, 2020: JAMA Oncology
#13
JOURNAL ARTICLE
Feliciano Barrón, Roberto Sánchez, Marisol Arroyo-Hernández, Carolina Blanco, Zyanya L Zatarain-Barrón, Rodrigo Catalán, Maritza Ramos-Ramírez, Andrés F Cardona, Diana Flores-Estrada, Oscar Arrieta
Introduction: Immune checkpoint inhibitor-related pneumonitis (ICIP) is a potentially life threatening immune-related adverse event (irAE), especially in non-small cell lung cancer (NSCLC) patients. Currently, the potential for increased irAE in patients who receive radiotherapy is scarcely known, although a connection between antitumor immune responses and irAEs has been suggested. In this study, we evaluated the development of ICIP in non-small cell lung cancer patients with prior radiotherapy, treated with immunotherapy in the second-line...
2020: Frontiers in Oncology
#14
REVIEW
Zhangfeng Huang, Wenhao Su, Tong Lu, Yuanyong Wang, Yanting Dong, Yi Qin, Dahai Liu, Lili Sun, Wenjie Jiao
Lung cancer is one of the most common cancers and the leading cause of cancer-related deaths worldwide. Most of these patients with non-small cell lung cancer (NSCLC) present with the advanced stage of the disease at the time of diagnosis, and thus decrease the 5-year survival rate to about 5%. Immune checkpoint inhibitors (ICIs) can act on the inhibitory pathway of cancer immune response, thereby restoring and maintaining anti-tumor immunity. There are already ICIs targeting different pathways, including the programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4) pathway...
2020: Frontiers in Pharmacology
#15
JOURNAL ARTICLE
Rei Hashimoto, Takehiro Ueda, Yukio Tsuji, Yoshihisa Otsuka, Kenji Sekiguchi, Riki Matsumoto
A 74-year-old man, who received pembrolizumab for the treatment for non-small cell lung cancer, developed quadriparesis 10 days after the first course of treatment accompanied by gait disturbance. Dysesthesia was observed in the distal extremities, and tendon reflexes were absent. Neurological examination and peripheral nerve conduction study supported the diagnosis of Guillain-Barré syndrome-like acute inflammatory demyelinating polyneuropathy caused by pembrolizumab. The administration of pembrolizumab was discontinued...
November 27, 2020: Rinshō Shinkeigaku, Clinical Neurology
#16
REVIEW
Giuseppe Lamberti, Monia Sisi, Elisa Andrini, Arianna Palladini, Francesca Giunchi, Pier-Luigi Lollini, Andrea Ardizzoni, Francesco Gelsomino
Treatment with inhibition of programmed cell death 1 (PD-1) or its ligand (PD-L1) improves survival in advanced non-small-cell lung cancer (NSCLC). Nevertheless, only a subset of patients benefit from treatment and biomarkers of response to immunotherapy are lacking. Expression of PD-L1 on tumor cells is the primary clinically-available predictive factor of response to immune checkpoint inhibitors, and its relevance in cancer immunotherapy has fostered several studies to better characterize the mechanisms that regulate PD-L1 expression...
October 26, 2020: Cancers
#17
MULTICENTER STUDY
Emily S Kowalski, Jill S Remick, Kai Sun, Gregory S Alexander, Rahul Khairnar, Emily Morse, Hua-Ren Cherng, Lars J Berg, Yannick Poirier, Narottam Lamichhane, Stewart Becker, Shifeng Chen, Jason K Molitoris, Young Kwok, William F Regine, Mark V Mishra
PURPOSE: Stereotactic radiation therapy (SRT) and immune checkpoint inhibitors (ICI) may act synergistically to improve treatment outcomes but may also increase the risk of symptomatic radiation necrosis (RN). The objective of this study was to compare outcomes for patients undergoing SRT with and without concurrent ICI. METHODS AND MATERIALS: Patients treated for BMs with single or multi-fraction SRT were retrospectively reviewed. Concurrent ICI with SRT (SRT-ICI) was defined as administration within 3 months of SRT...
October 27, 2020: Radiation Oncology
#18
JOURNAL ARTICLE
Jade L Hefler, Lauren M Bailey, Cynthia El Rahi, Amy C Schefler, Eric H Bernicker
BACKGROUND: Immunotherapy with checkpoint inhibitors has demonstrated durable responses and remarkable antitumor effects in a variety of cancers. Although these agents are generally well-tolerated, patients can experience immune-related adverse events (irAEs) that require prompt recognition by healthcare providers. Immune-related ocular toxicities are rare, but serious adverse events have been reported with the use of checkpoint inhibitors. Case presentation: Here, we describe a rare case of panuveitis during Nivolumab and Ipilimumab combination treatment in a patient being treated for recurrent Small Cell Lung Cancer (SCLC)...
October 27, 2020: Journal of Oncology Pharmacy Practice
#19
JOURNAL ARTICLE
Alexandra Drakaki, Preet K Dhillon, Heather Wakelee, Stephen Y Chui, Jinjoo Shim, Matthew Kent, Viraj Degaonkar, Tien Hoang, Virginia McNally, Patricia Luhn, Ralf Gutzmer
Immune checkpoint inhibitors (CPIs) have expanded treatment options for patients with solid tumors. Systemic corticosteroids (CSs) have an indispensable role in cancer care, but CS-related immunosuppression may counteract the CPI-driven antitumor immune response. This retrospective study investigated the association between baseline CS use (bCS; ≤14 days before, ≤30 days after CPI initiation) and clinical outcomes in patients with advanced non-small cell lung cancer (aNSCLC), melanoma (aMel), or urothelial carcinoma (aUC)...
October 5, 2020: Oncoimmunology
#20
JOURNAL ARTICLE
Nathan Leclair, Rebecca Calafiore, Wu Qian, Leo Wolansky, Ketan Bulsara
Non-small cell lung cancer (NSCLC) is frequently associated with central nervous system metastases resulting in poor outcomes. As newer targeted therapies become available determining which patients can benefit from these therapies has remained challenging, and current molecular testing options rely on a panel of only a handful of known oncogenic drivers. Here we demonstrate a targeted approach at uncovering clinically relevant variants in cancer-associated genes using genomic sequencing. Our patient underwent targeted sequencing of 212 cancer-associated genes, revealing mutations in six; two of which were in EGFR, an important target for therapy in NSCLC...
October 19, 2020: Neuro-Chirurgie
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
